Background
This six-year retrospective study provides an in-depth analysis of the epidemiological and clinical patterns associated with
Acinetobacter baumannii
(
A. baumannii
) infections, focusing on age distribution, antibiotic resistance profiles, and specimen types.
Aim
The research examines the incidence and characteristics of
both
non-Multi-Drug Resistant (non-MDR) and Multi-Drug Resistant (MDR)
A. baumannii
strains by reviewing patient records from January 2016 to December 2022.
Methods
Through a statistical analysis, the study highlights the incidence rates across diverse age groups and explores the impact of antibiotic treatment regimens on infection outcomes. Additionally, it identifies the primary clinical specimen types for each strain, noting an association between non-MDR
A. baumannii
and midstream urine samples, while MDR
A. baumannii
strains were more frequently found in respiratory, wound, peripheral, and central line swaps/specimens.
Results
The results indicate that in 2016, non-MDR
A. baumannii
infections were notably more frequent compared to MDR
A. baumannii
cases. However, a significant shift occurred in 2021 and 2022, with a marked decrease in non-MDR
A. baumannii
cases and an increase in MDR
A. baumannii
infections. Antibiotic susceptibility testing revealed that non-MDR strains were commonly tested against cefazolin, ceftazidime, ciprofloxacin, gentamicin, nitrofurantoin, oxacillin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole. In contrast, MDR strains were frequently tested against amikacin, cefepime, colistin, meropenem, imipenem, and tigecycline.
Conclusion
This study enhances the understanding of
A. baumannii
clinical behaviour and resistance patterns, offering valuable insights to support future research and inform strategies for infectious disease management and control.